Thyquidity is a drug owned by Azurity Pharmaceuticals Inc. It is protected by 1 US drug patent filed in 2021 out of which none have expired yet. Based on its patents and exclusivities, its generic launch date is estimated to be Aug 06, 2031. Details of Thyquidity's patents and their expiration are given in the table below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | |||
| US9050307 | Method for the preparation of a levothyroxine solution |
Aug, 2031
(7 years from now) | Active |
A patent's expiry date may change depending upon legal activities going on that patent. Critical activities like abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease the life of a patent hence affecting its expiry date and in turn affecting the generic launch date of that drug. Tracking these ongoing activities on a patent application helps to keep an eye on the latest developments in the patent process of the drug which can give an idea of how early a drug's generic could be available. The next section provides a list of recent legal activities on Thyquidity's patents.
Latest Legal Activities on Thyquidity's Patents
Given below is the list of recent legal activities going on the following patents of Thyquidity.
| Event | Date | Patent/Publication |
|---|---|---|
 | ||
| Payment of Maintenance Fee, 8th Yr, Small Entity | 07 Dec, 2022 | US9050307 |
| Payment of Maintenance Fee, 4th Yr, Small Entity | 26 Nov, 2018 | US9050307 |
| Post Issue Communication - Certificate of Correction | 13 Jul, 2016 | US9050307 |
| Post Issue Communication - Certificate of Correction | 18 Mar, 2016 | US9050307 |
| Application ready for PDX access by participating foreign offices | 31 Aug, 2015 | US9050307 |
| Recordation of Patent Grant Mailed | 09 Jun, 2015 | US9050307 |
| Patent Issue Date Used in PTA Calculation | 09 Jun, 2015 | US9050307 |
| Email Notification | 21 May, 2015 | US9050307 |
| Issue Notification Mailed | 20 May, 2015 | US9050307 |
| Dispatch to FDC | 08 May, 2015 | US9050307 |
Several oppositions have been filed on Thyquidity's European patents. EP oppositions can significantly impact the timeline for the generic launch of drugs. If an opposition results in the revocation or amendment of a patent, it can shorten the exclusivity period of the original drug. This can lead to an earlier entry of generic versions into the market. To help you estimate the potential early arrival of Thyquidity's generic, the next section provides detailed information on ongoing and past EP oppositions related to Thyquidity patents.
Thyquidity's oppositions filed in EPO
Thyquidity has faced multiple oppositions in the European Patent Office. The earliest opposition was filed on Jul 11, 2016, by Uni-Pharma Kleon Tsetis Pharmaceutical Laboratories S.A.. This opposition was filed on patent number EP11711688A. Click below to reveal the latest opposition data.
| Application | Filing Date | Opposition Party | Legal Status |
|---|---|---|---|
 | |||
| EP11711688A | Jul, 2016 | Uni-Pharma Kleon Tsetis Pharmaceutical Laboratories S.A. | Granted and Under Opposition |
US patents provide insights into the exclusivity only within the United States, but Thyquidity is protected by patents in multiple countries. Understanding the full scope of patent protection is crucial in strategizing market entry. By looking at the broader patent landscape, you can identify markets with weaker patent protection which could be ideal generic entry points. The following section offers details on Thyquidity's family patents as well as insights into ongoing legal events on those patents.
Thyquidity's family patents
Coming Soon
Patent Strength Analyzer
YesNo
Thank you for your response 🥳
Generic Launch
Generic Release Date:
Thyquidity's generic launch date based on the expiry of its last outstanding patent is estimated to be Aug 06, 2031 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)
Thyquidity Generics:
Levothyroxine Sodium is the generic name for the brand Thyquidity. 14 different companies have already filed for the generic of Thyquidity, with Mylan having the maximum number of approved applications. Check out the entire list of companies who have already received approval for Thyquidity's generic
How can I launch a generic of Thyquidity before its drug patent expiration? :
You can seek FDA approval to launch a generic drug before the expiration of Thyquidity's patents related by providing a 'paragraph IV certification' in your application, which states that the patent submitted by the Thyquidity's sponsor is invalid, unenforceable, or will not be infringed by your generic product.
Given below are the details of the already filed Para IV certificates on Thyquidity -
| Strength | Submission Date | ANDA(s) Filed | First applicant approval | Last patent expiry | 180 day status |
|---|---|---|---|---|---|
| 100 mcg/5 mL | 28 Dec, 2022 | 1 | 06 Aug, 2031 |
About Thyquidity
Thyquidity is a drug owned by Azurity Pharmaceuticals Inc. Thyquidity uses Levothyroxine Sodium as an active ingredient. Thyquidity was launched by Azurity in 2020.
Market Authorisation Date:
Thyquidity was approved by FDA for market use on 30 November, 2020.
Active Ingredient:
Thyquidity uses Levothyroxine Sodium as the active ingredient. Check out other Drugs and Companies using Levothyroxine Sodium ingredient
Dosage:
Thyquidity is available in solution form for oral use. Given below is detailed information on Dosage -
| Strength | Dosage Form | Availability | Application Pathway |
|---|---|---|---|
| 100MCG/5ML | SOLUTION | Prescription | ORAL |